Zhongmou Therapeutics

Zhongmou Therapeutics has a world-leading comprehensive platform system for optogenetic gene therapy, dedicated to bringing innovative treatments to patients with degenerative retinal diseases worldwide. The optogenetic gene therapy method involves delivering genes that encode light-sensitive proteins to retinal cells via an AAV vector, enabling the retina to express a special functional protein sensitive to light. These light-sensitive proteins are activated by natural external light and generate visual signal information that is transmitted to the brain, thereby restoring vision and improving the patient's eyesight.